An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]
Survey of disease indications for a comparative biology-based drug discovery platform
February 06, 2020
The BCBA project team will conduct a survey to evaluate and prioritize cardiovascular, metabolic, and neuro indications for an early stage company’s target discovery platform that leverages the power of comparative biology to develop therapeutics.
Market opportunity assessment for a novel all-in-one NGS analysis library prep solution
July 7, 2020
The project team will analyze the market opportunity for a novel NGS library preparation kit for Illumina NGS systems that, in addition to primary sequence, captures long-range information enabling large structural variant detection and haplotype phasing along with 3D chromatin architecture.
Market opportunity assessment of novel bispecific antibodies for immuno-oncology
September 25, 2020
An early-stage therapeutics company is developing novel T-cell-engaging bispecific antibodies that enable targeted stimulation of the immune system to kill tumor cells.
Market opportunity assessment for a high-throughput biologic manufacturing platform
February 19, 2021
An early-stage, global health focused platform company has developed methods to rapidly generate a variety of biologics inexpensively and in high throughput. The company is interested in understanding how to best position themselves in the market based on the competitive advantages that their platform provides. In particular, the company believes that the flexibility and rapid […]
Application prioritization for a next-generation antibody design and characterization platform
March 12, 2021
An early stage protein therapeutics company has developed a novel AI-driven platform for rapid, iterative antibody design and characterization and is in the process of prioritizing applications of their platform for a set of initial Proof of Concept (POC) programs. To that end, the BCBA project team will 1) evaluate the current research and framework […]
Optimization of a direct-to-consumer test for the assessment of chronic inflammation
March 26, 2021
A direct-to-consumer (DTC) diagnostics company is developing a blood test panel for the assessment of chronic inflammation. Using a cutting-edge AI-based platform, the company is optimizing a panel that can provide their customers with deep insights on their inflammatory status with only a few drops of blood. Given the massive increase in DTC and telemedicine […]